BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30503706)

  • 1. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence.
    Lu B; Klingbeil O; Tarumoto Y; Somerville TDD; Huang YH; Wei Y; Wai DC; Low JKK; Milazzo JP; Wu XS; Cao Z; Yan X; Demerdash OE; Huang G; Mackay JP; Kinney JB; Shi J; Vakoc CR
    Cancer Cell; 2018 Dec; 34(6):970-981.e8. PubMed ID: 30503706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription.
    Mak AB; Nixon AM; Moffat J
    Cancer Res; 2012 Apr; 72(8):1929-34. PubMed ID: 22337994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.
    Jaracz-Ros A; Lewandowski D; Barroca V; Lavau C; Roméo PH
    Haematologica; 2011 Dec; 96(12):1770-8. PubMed ID: 21933859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
    Sano K
    Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C.
    Schwieger M; Schüler A; Forster M; Engelmann A; Arnold MA; Delwel R; Valk PJ; Löhler J; Slany RK; Olson EN; Stocking C
    Blood; 2009 Sep; 114(12):2476-88. PubMed ID: 19584403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular functions of common and atypical MLL fusion protein complexes.
    Takahashi S; Yokoyama A
    Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194548. PubMed ID: 32320750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
    Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
    Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
    Zhang Y; Owens K; Hatem L; Glass CH; Karuppaiah K; Camargo F; Perkins AS
    Blood; 2013 Oct; 122(16):2888-92. PubMed ID: 24021671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.
    Zeleznik-Le NJ; Harden AM; Rowley JD
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10610-4. PubMed ID: 7938000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menin as a hub controlling mixed lineage leukemia.
    Thiel AT; Huang J; Lei M; Hua X
    Bioessays; 2012 Sep; 34(9):771-80. PubMed ID: 22829075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
    Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
    Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
    Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
    Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reciprocal world of MLL fusions: A personal view.
    Marschalek R
    Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194547. PubMed ID: 32294539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
    Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
    Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic description of MLL fusion gene formation.
    Wright RL; Vaughan AT
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):283-91. PubMed ID: 24787275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.